Keywords: novartis, terbinafine, launched, otc, usa, take, athlete
Novartis' terbinafine launched OTC in USA to take on athlete's foot market
Article | 13 May 1999
Novartis' Lamisil (terbinafine), the best-selling prescriptionmedication in the USA for athlete's foot with more than a million prescriptions in 1998, is ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Italy's pharma market slump set to continue, warns GlobalData
